51. Old and New Beta-Lactamase Inhibitors: Molecular Structure, Mechanism of Action, and Clinical Use
- Author
-
Claudia Siracusa, Davide Carcione, Valerio Leoni, Jari Intra, Adela Sulejmani, Carcione, D, Siracusa, C, Sulejmani, A, Leoni, V, and Intra, J
- Subjects
Microbiology (medical) ,Carbapenem ,antibiotic resistance ,β-lactam ,medicine.drug_class ,Antibiotics ,cephalosporin ,Review ,RM1-950 ,Bioinformatics ,Biochemistry ,Microbiology ,carbapenem ,Antibiotic resistance ,β lactamase inhibitor ,medicine ,β-lactamase inhibitor ,Pharmacology (medical) ,General Pharmacology, Toxicology and Pharmaceutics ,Beta-Lactamase Inhibitors ,business.industry ,β-lactams ,Treatment options ,Penicillin ,Infectious Diseases ,penicillin ,Mechanism of action ,Therapeutics. Pharmacology ,medicine.symptom ,business ,medicine.drug - Abstract
The β-lactams have a central place in the antibacterial armamentarium, but the increasing resistance to these drugs, especially among Gram-negative bacteria, is becoming one of the major threats to public health worldwide. Treatment options are limited, and only a small number of novel antibiotics are in development. However, one of the responses to this threat is the combination of β-lactam antibiotics with β-lactamase inhibitors, which are successfully used in the clinic for overcoming resistance by inhibiting β-lactamases. The existing inhibitors inactivate most of class A and C serine β-lactamases, but several of class D and B (metallo-β-lactamase) are resistant. The present review provides the status and knowledge concerning current β-lactamase inhibitors and an update on research efforts to identify and develop new and more efficient β-lactamase inhibitors.
- Published
- 2021